What Evamed does

Evamed is a France-based clinical research company founded in 2005 and headquartered in Hérouville-Saint-Clair, Normandy. The firm specializes in the evaluation and clinical investigation of medical devices, serving medical device developers that require clinical evidence generation and regulatory-grade clinical investigation support within European frameworks.

The company operates as a privately held, for-profit organization with a workforce in the 11-50 employee band. Its functional scope centers on clinical evaluation and clinical investigation of medical devices, indicating a service offering built around clinical trial execution, clinical evaluation reports, and supporting evidence generation for medical device regulatory submissions. Beyond the firmographic core, the company description provided in the input is thin: no products, proprietary platforms, named customers, revenue, or pricing disclosures are explicitly attached to Evamed. The company website (evamed.fr) is the primary public reference point identified.

Evamed's business model and go-to-market specifics are not disclosed in the supplied data. As a small European specialty CRO with no listed investors beyond an early-stage incubation engagement from Normandie Incubation in December 2005, the operating model is consistent with a boutique clinical research services firm rather than a scaled enterprise CRO. Customer segment data, contract structure, and revenue mechanics are not provided, which limits the ability to characterize the commercial model in detail.

Name

Evamed

Legal name

1MED SA

Website

https://evamed.fr

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Evamed is a France-based clinical research company founded in 2005 that specializes in the evaluation and clinical investigation of medical devices for medical device developers. It operates as a privately held boutique CRO with 11-50 employees based in Hérouville-Saint-Clair.

Ownership category

akta.pro rank

Product category

Medical Device Clinical Research Services (MedTech CRO)

NAICS

Medical and Diagnostic Laboratories (62151), Custom Computer Programming Services (541511)

SIC

Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)

akta.pro primary industry

Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management (HLACAOAI)

akta.pro secondary industries

Quality, Compliance & Validation Software for Labs (GxP/CSV, eQMS for QC Labs) (HLAGAJAI), Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN)

Keywords

• Clinical research services
• Medical device evaluation
• Regulatory consultancy
• Clinical trial management
• Post-market surveillance

Headquarters

HQ city

Hérouville-saint-clair

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. CRO Services: Full-service clinical research organization services including clinical trial management, pre and post market trial support, regulatory consultancy, and quality management. Services span product development from implementation of Quality Management Systems (ISO 13485) to regulatory documentation and clinical studies across all phases in Europe and beyond.
2. Digital Solutions (1Survey+): Clinical-grade digital platform subscription for PMCF, PMS, Real-World Evidence, and technical documentation. Platform provides data collection that transforms directly into regulatory documentation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Evamed is a specialty MedTech clinical research organization that delivers clinical and regulatory support, quality management, clinical trial management, pre- and post-market trial services, biometrics, and medical writing for medical device and combination product developers across Europe and beyond. Its flagship digital offering, 1Survey+, is the first clinical-grade platform purpose-built for Post-Market Clinical Follow-Up (PMCF) and Real-World Evidence generation, embedding EU MDR standards, ISO 14155-aligned methodology, blockchain-based data validation, and integrated AI quality monitoring into a single validated process.

Product overview

1MED operates as a specialty MedTech and combination product CRO offering clinical and regulatory support, quality management, clinical trial management, pre and post market trial support, biometrics, medical writing, and digital solutions. The company's primary digital product is 1Survey+, a clinical-grade platform for PMCF and Real-World Evidence generation. Additional service offerings include Regulatory Services, Quality Services, CRO Services for the MedTech industry, CRO Services for Combination Products, and Post-Market Services.

Differentiator

Problem solved

Functional benefit

Brands

• 1Survey+: The first clinical-grade platform for PMCF (Post-Market Clinical Follow-up) and Real-World Evidence. Engineered to meet MDR standards, it generates Level-4 evidence aligning clinical methodology, ISO 14155 expectations, and real-time data integrity into a validated process. Features include AI agents for quality monitoring and real-time blockchain validation.

Products and services

• 1Survey+

Quantifiable outcome

• Level-4 clinical evidence generation

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• TÜVcoreStrategic or Co-development PartnerTÜV, a leading Notified Body, collaborates with 1MED on educational webinars focused on MDR compliance, data quality, and PMCF strategies. The partnership includes joint events such as webinars featuring TÜV experts discussing audit pitfalls, ISO 14155 requirements, and defensible PMCF data strategies.

Scale indicators2 records

Recent moves1 record

Direct peers

• NAMSA: NAMSA is the world's leading specialty MedTech CRO offering regulatory, quality, clinical, and laboratory services across the device lifecycle. It is the closest direct peer to 1MED given its MedTech-only focus and full continuum of MDR/IVDR-aligned services.
• RQM+ (formerly RCRI): RQM+ is a MedTech-focused regulatory, quality, and clinical consultancy serving device OEMs under MDR/IVDR. Highly comparable to 1MED in niche specialty CRO positioning, regulatory depth, and combination-product expertise.

Broad incumbents

• Medpace: Medpace is a large global CRO with a dedicated medical device and diagnostics unit offering clinical trial management, regulatory support, and biometrics. It competes with 1MED on MedTech trials but serves many more therapeutic verticals at much larger scale.
• ICON plc: ICON is one of the largest global CROs with a dedicated medical device and combination product practice through its Medical Device & Diagnostics Research group. They overlap with 1MED on regulatory-clinical services for MedTech sponsors but offer a much broader service portfolio.
• Charles River Laboratories: Charles River operates a global CRO business that includes medical device and IVD clinical and regulatory services via its CDMO/CRO network. Comparable to 1MED in clinical and regulatory depth for MedTech, but operates at much larger scale and broader life-science scope.
• IQVIA: IQVIA is the world's largest CRO with a MedTech and devices practice spanning regulatory affairs, clinical operations, and real-world evidence. It competes with 1MED primarily on the largest MedTech engagements requiring global reach and integrated technology.
• Eurofins Scientific: Eurofins provides testing, certification, and clinical research services to MedTech and IVD developers including MDR/IVDR testing and clinical studies. It overlaps with 1MED on IVD and MedTech clinical evidence work but is fundamentally a broader testing-and-laboratory conglomerate.
• WuXi AppTec: WuXi AppTec provides global CRO and CDMO services with a clinical research arm supporting medical device and combination product sponsors. Comparable as a broad-scope life sciences services platform, though WuXi's depth on MedTech-specific PMCF is more limited than 1MED's specialty focus.

Others

• TÜV SÜD: TÜV SÜD is a Notified Body and certification provider that partners with 1MED on PMCF and MDR-compliance webinars. While not a CRO, TÜV SÜD's adjacent regulatory and medical device testing services frame 1MED's competitive set and partner ecosystem.

Emerging players

• Catalent (now Novo Holdings-owned): Catalent provides clinical and combination-product development services for drug-device developers. While pharma-biased, its combination-product and biologics-clinical capabilities overlap with 1MED's combination-product CRO offering for MedTech OEMs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/Evamed_

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evamed